Welcome to our dedicated page for Ptc SEC filings (Ticker: PTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC’s SEC disclosures can feel like deciphering a digital-twin schematic: pages of subscription ARR tables, intangible asset roll-forwards, and segment revenue splits that bury the insights you actually need. If you have ever searched for “understanding PTC SEC documents with AI� or wondered how acquisitions affect deferred revenue, you know the challenge.
Stock Titan eliminates that complexity. Our AI reviews every PTC quarterly earnings report 10-Q filing and annual report 10-K, highlighting where Windchill drives growth, how Creo R&D spend moves margins, and what the latest 8-K material events mean. Receive real-time alerts for PTC insider trading Form 4 transactions, then dive into plain-English summaries that turn technical jargon into actionable context. Whether it’s a sudden 8-K on a strategic acquisition, a proxy statement executive compensation table, or Form 4 insider transactions in real time, the platform keeps each document one click away and explained simply.
What investors track here:
- PTC executive stock transactions Form 4 and share-based compensation trends.
- Subscription vs perpetual license mix inside every PTC earnings report filing analysis.
- Goodwill and intangible impairment signals surfaced from the PTC annual report 10-K simplified.
- Board proposals and pay packages detailed in the PTC proxy statement executive compensation section.
No more wading through hundreds of pages to find one metric. With AI-powered summaries, expert context, and EDGAR-speed updates, PTC SEC filings explained simply are now at your fingertips.
Q2 2025 snapshot (Perdoceo Education � PRDO):
- Revenue surged 25.7 % YoY to $209.6 m, aided by the Dec-24 USAHS acquisition (18 % of quarterly sales) and continued growth at legacy units.
- Operating income climbed 11.7 % to $51.4 m; net income up 6.8 % to $41.0 m, delivering diluted EPS of $0.62 versus $0.57.
- YTD revenue $422.6 m (+26 %), net income $84.7 m (+8.8 %). Operating cash flow strengthened to $143.9 m (+55 %).
- Cash, equivalents & short-term investments reached $659.6 m after $46.1 m of buybacks (1.6 m shares) and $17.7 m in dividends; only $1 m remained under the prior $50 m authorization, but a new $75 m program was approved 7/31/25.
- Segment mix: CTU 56 % of revenue, AIUS 26 %, USAHS 18 % (-$2.0 m YTD operating loss during integration).
- Gross deferred revenue rose to $113.6 m, reflecting higher billing and enrollment; allowance for credit losses stable at $42.3 m.
- Balance sheet still debt-light; a $56.8 m failed sale-leaseback created a financing liability. Total cash plus investments exceed all liabilities by ~$675 m.
- Effective tax rate eased to 27.0 % (benefit from stock-comp and reserve releases).
- Regulatory/legal: DOJ False Claims Act suit and new CID remain unresolved; litigation reserve $1.5 m.
Takeaway: Solid top-line growth and cash generation offset margin dilution from USAHS and higher depreciation. Ample liquidity supports continued buybacks and dividends, while integration execution and regulatory outcomes are key watch items.